Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Tona M. Gilmer"'
Autor:
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson
Publikováno v:
Cell Reports, Vol 4, Iss 6, Pp 1090-1099 (2013)
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not
Externí odkaz:
https://doaj.org/article/def1fcb2813549cea0a237cf8e63bb48
Autor:
Dustin M. Walters, James M. Lindberg, Sara J. Adair, Timothy E. Newhook, Catharine R. Cowan, Jayme B. Stokes, Cheryl A. Borgman, Edward B. Stelow, Bryce T. Lowrey, Maria E. Chopivsky, Tona M. Gilmer, John T. Parsons, Todd W. Bauer
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 2, Pp 143-155 (2013)
Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor receptor (EGFR) and human EGFR2 (HER2) is observed frequent in pancreatic adenocarcinomas. Because of co-activation of these
Externí odkaz:
https://doaj.org/article/9fb804b7b7d4409cb4093fdefaf8b552
Autor:
Tona M. Gilmer, Li Liu, Sylvie G. Laquerre, Scott H. Dickerson, Kimberly N. Smitheman, Ashley M. Hughes, Maureen R. Bleam, Vivian Zhang, Stephen D. Eastman, James G. Greger
PDF file - 276K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::612cd6282bf70c0b319d1c53a2e6856c
https://doi.org/10.1158/1535-7163.22499103.v1
https://doi.org/10.1158/1535-7163.22499103.v1
Autor:
Tona M. Gilmer, Anne-Marie Martin, James Greger, John Peterson, Amber Anderson, Yuan Liu, Hong Shi, Li Liu
Supplementary Figure 1 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d296dd87f42ea39299fddb3f5047092
https://doi.org/10.1158/1535-7163.22496599
https://doi.org/10.1158/1535-7163.22496599
Autor:
Tona M. Gilmer, Anne-Marie Martin, James Greger, John Peterson, Amber Anderson, Yuan Liu, Hong Shi, Li Liu
Supplementary Figure 2 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58cda9467342fdee99871d058d275af5
https://doi.org/10.1158/1535-7163.22496596.v1
https://doi.org/10.1158/1535-7163.22496596.v1
Autor:
Tona M. Gilmer, Li Liu, Sylvie G. Laquerre, Scott H. Dickerson, Kimberly N. Smitheman, Ashley M. Hughes, Maureen R. Bleam, Vivian Zhang, Stephen D. Eastman, James G. Greger
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown encouraging response rates; however, the duration of response has been limited. To identify determinants of acquired resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::342d7af81845cc3449fb50863d2f5fa4
https://doi.org/10.1158/1535-7163.c.6536067
https://doi.org/10.1158/1535-7163.c.6536067
Autor:
Tona M. Gilmer, Anne-Marie Martin, James Greger, John Peterson, Amber Anderson, Yuan Liu, Hong Shi, Li Liu
Supplementary Figure 3 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298d1229f9ff462f92e97abcb1dc2370
https://doi.org/10.1158/1535-7163.22496593
https://doi.org/10.1158/1535-7163.22496593
Autor:
Tona M. Gilmer, Anne-Marie Martin, James Greger, John Peterson, Amber Anderson, Yuan Liu, Hong Shi, Li Liu
Supplementary Material and Methods, Figure Legends and Tables 1-2 from Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94114131285dea18fa90a3b1fa85087e
https://doi.org/10.1158/1535-7163.22496590.v1
https://doi.org/10.1158/1535-7163.22496590.v1
Autor:
Tona M. Gilmer, Anne-Marie Martin, James Greger, John Peterson, Amber Anderson, Yuan Liu, Hong Shi, Li Liu
The HER and MET receptor tyrosine kinases (RTK) are coactivated in a subset of human tumors. This study characterizes MET and HER expression and signaling in a panel of human tumor cell lines and the differential susceptibility of these cell lines to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b508d70e532df65d9353006adc0e672
https://doi.org/10.1158/1535-7163.c.6535330
https://doi.org/10.1158/1535-7163.c.6535330
Autor:
Mui Cheung, Deirdre K. Luttrell, Jeffrey A. Stafford, Amogh Boloor, Andrea H. Epperly, Anne T. Truesdale, Tona M. Gilmer, Robert J. Mullin, James A. Onori, Laura E. Harrington, Charles G. Miller, Teresa M. Hopper, Ming-Chih Crouthamel, Renae M. Crosby, Jennifer H. Johnson, Sharon K. Rudolph, Victoria B. Knick, Rakesh Kumar
Supplementary Fig. S2 from Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef45f85ad8f9bf67422b660c7c3c6e9f
https://doi.org/10.1158/1535-7163.22486202
https://doi.org/10.1158/1535-7163.22486202